New drug combo targets tough cancers in early trial
NCT ID NCT06870487
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center.
Seattle, Washington, 98109, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
University of Washington Medical Center- Montlake
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.